Theravance Biopharma, Inc. Derivative Asset, Noncurrent
Theravance Biopharma, Inc. (TBPH) had Derivative Asset, Noncurrent of $2.37 million as of 2025-06-30, per its 10-Q filed 2025-08-13.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:DerivativeAssetsNoncurrent · last filed 2025-08-13
- 2025-06-30: Derivative Asset, Noncurrent $2.37M.
- 2025-03-31: Derivative Asset, Noncurrent $2.33M.
- 2024-12-31: Derivative Asset, Noncurrent $2.29M.
| Period end | Derivative Asset, Noncurrent |
|---|---|
| 2025-06-30 | $2.37M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $2.33M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $2.29M 10-Q · filed 2025-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |